TSH Biopharm Corporation Limited (TPEX:8432)

Market Cap	2.15B -2.8%
Revenue (ttm)	1.27B +20.9%
Net Income	125.02M +4.5%
EPS	3.25 +4.5%
Shares Out	38.40M
PE Ratio	17.23
Forward PE	n/a
Dividend	2.12 (3.79%)
Ex-Dividend Date	Jun 16, 2025

Volume	30,114
Average Volume	44,328
Open	56.20
Previous Close	56.60
Day's Range	55.80 - 56.30
52-Week Range	43.00 - 60.70
Beta	0.36
RSI	47.50
Earnings Date	Feb 24, 2026

About TSH Biopharm Corporation

TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others. It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid biopsy test designed for MRD detection and surveillance in stage I-III solid tumor patients; AlphaLiquid 100, a liquid biopsy test designed for patient...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 76
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 8432

Financial Performance

In 2024, TSH Biopharm Corporation's revenue was 1.12 billion, an increase of 37.59% compared to the previous year's 810.92 million. Earnings were 113.09 million, an increase of 82.44%.